References
- Iannone F, Lapadula G. Obesity and inflammation – targets for OA therapy. Curr Drug Targets 2010;11:586–98.
- Bremmer S, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, . Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2010;63:1058–69.
- Murray ML, Bergstresser PR, Adams-Huet B, Cohen JB. Relationship of psoriasis severity to obesity using same-gender siblings as controls for obesity. Clin Exp Dermatol 2009; 34:140–4.
- Bardazzi F, Balestri R, Baldi E, Antonucci A, De Tommaso S, Patrizi A. Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy. Dermatol Ther 2010;23(Suppl 1):S14–19.
- Cassano N, Galluccio A, De Simone C, Loconsole F, Massimino SD, Plumari A, . Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data. J Biol Regul Homeost Agents 2008;22:233–7.
- Di Lernia V, Tasin L, Pellicano R, Zumiani G, Albertini G. Impact of body mass index on retention rates of anti-TNF-α drugs in daily practice for psoriasis. J Dermatolog Treat. Published online: 24 July 2011. doi:10.3109/09546634.2011.593489.
- Kyle S, Chandler D, Griffiths CE, Helliwell P, Lewis J, McInnes I, . Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology (Oxford) 2005;44:390–7.
- Di Minno MN, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R, . Obesity and the prediction of minimal disease activity. A prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken). Published online: 18 April 2012. doi:10.1002/acr.21711.
- Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, . Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73.
- Jacobsson LTH, Hetland ML. New remission criteria for RA: ‘modern times’ in rheumatology – not a silent film, rather a 3D movie. Ann Rheum Dis 2011;70:401–3.
- van Gestel AM, Prevoo ML, van ‘t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34–40.
- Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, . Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006;65:1373–8.
- Navarro-Sarabia F, Ruiz-Montesinos D, Hernandez B, Navarro-Compán V, Marsal S, Barcelo M, . DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists. BMC Musculoskelet Disord 2009;10:91.
- Saad AA, Ashcroft DM, Watson KD, Symmons DP, Noyce PR, Hyrich KL, . Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010;49:697–705.